Drug intelligence / Profile preview

RP525

Development stage: Preclinical
Lead developer: RESprotect
Modality: Small Molecules

Overview

RP525 is a second-generation nucleoside derivative developed by RESprotect for the treatment of cancer. It is designed to target Heat Shock Protein 27 (Hsp27), a molecular chaperone that is frequently overexpressed in various malignancies and contributes to tumor cell survival and resistance to chemotherapy. As a derivative of RP101 (brivudine), RP525 is intended to modulate Hsp27 function, thereby sensitizing cancer cells to standard treatments and preventing the development of drug resistance. The compound is currently in the preclinical stage of development.

Targets

HSPB1 (Heat shock protein beta-1)

Beyond the preview

Go deeper on RP525.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RP525.

Explore the full profile